Paragon Genomics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Later Stage VC
- Investors
-
10
Paragon Genomics General Information
Description
Developer of targeted sequencing technologies designed to provide target enrichment services to the genomics community to advance precision medicine and research. The company's PCR-based technologies provide comprehensive services to diagnostics in oncology, infectious disease, inherited disease, reproductive health, neurology, cardiology, and other applications, enabling NGS labs to develop targeted sequencing assays that are fast, accurate, sensitive, and cost-effective.
Contact Information
Website
www.paragongenomics.comCorporate Office
- 5020 Brandin Court
- Floor 2
- Fremont, CA 94538-3140
- United States
Corporate Office
- 5020 Brandin Court
- Floor 2
- Fremont, CA 94538-3140
- United States
Paragon Genomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | Completed | Generating Revenue | ||||
| 4. Debt - PPP | 30-Apr-2020 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 12-Sep-2017 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Sep-2016 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Paragon Genomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Paragon Genomics Comparisons
Industry
Financing
Details
Paragon Genomics Competitors (55)
One of Paragon Genomics’s 55 competitors is Standard BioTools, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Standard BioTools | Formerly VC-backed | Boston, MA | ||||
| CD Genomics | Corporation | Shirley, NY | ||||
| Watchmaker Genomics | Venture Capital-Backed | Boulder, CO | ||||
| Eurofins DiscoverX Products | Formerly VC-backed | Fremont, CA | ||||
| Caris Life Sciences | Formerly PE-Backed | Irving, TX |
Paragon Genomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Paragon Genomics Patents
Paragon Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11680293-B1 | Methods and compositions for amplifying dna and generating dna sequencing results from target-enriched dna molecules | Active | 21-Apr-2022 | ||
| US-12091715-B2 | Methods and compositions for reducing base errors of massive parallel sequencing using triseq sequencing | Active | 21-Apr-2022 | ||
| US-20230340588-A1 | Methods and compositions for reducing base errors of massive parallel sequencing using triseq sequencing | Active | 21-Apr-2022 | ||
| US-20210363517-A1 | High throughput amplification and detection of short rna fragments | Inactive | 20-May-2020 | ||
| US-10941453-B1 | High throughput detection of pathogen rna in clinical specimens | Active | 20-May-2020 | C12Q1/701 |
Paragon Genomics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Paragon Genomics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cloudstone Capital | Venture Capital | Minority | ||
| Co-Win Ventures | Venture Capital | Minority | ||
| Fosun Industrial Holdings | Corporation | Minority | ||
| Angel (individual) | Minority | |||
| Heda Ventures | Venture Capital | Minority |
Paragon Genomics FAQs
-
When was Paragon Genomics founded?
Paragon Genomics was founded in 2015.
-
Where is Paragon Genomics headquartered?
Paragon Genomics is headquartered in Fremont, CA.
-
What is the size of Paragon Genomics?
Paragon Genomics has 17 total employees.
-
What industry is Paragon Genomics in?
Paragon Genomics’s primary industry is Discovery Tools (Healthcare).
-
Is Paragon Genomics a private or public company?
Paragon Genomics is a Private company.
-
What is Paragon Genomics’s current revenue?
The current revenue for Paragon Genomics is .
-
How much funding has Paragon Genomics raised over time?
Paragon Genomics has raised $8M.
-
Who are Paragon Genomics’s investors?
Cloudstone Capital, Co-Win Ventures, Fosun Industrial Holdings, , and Heda Ventures are 5 of 10 investors who have invested in Paragon Genomics.
-
Who are Paragon Genomics’s competitors?
Standard BioTools, CD Genomics, Watchmaker Genomics, Eurofins DiscoverX Products, and Caris Life Sciences are some of the 55 competitors of Paragon Genomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
